VIATRIS INC. Payments for (Proceeds from) Other Investing Activities
VIATRIS INC. (VTRS) reported Payments for (Proceeds from) Other Investing Activities of $83.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsForProceedsFromOtherInvestingActivities · last filed 2026-08-06
- VIATRIS INC. payments for (proceeds from) other investing activities for the quarter ending 2026-06-30 was $1.00M, a 16.67% decline year-over-year.
- VIATRIS INC. payments for (proceeds from) other investing activities for the quarter ending 2026-03-31 was $82.00M, a 336.17% increase year-over-year.
- VIATRIS INC. payments for (proceeds from) other investing activities for the quarter ending 2025-12-31 was $2.60M, a 271.43% increase year-over-year.
- VIATRIS INC. payments for (proceeds from) other investing activities for the quarter ending 2025-09-30 was $12.90M, a 53.57% increase year-over-year.
- VIATRIS INC. payments for (proceeds from) other investing activities for fiscal 2025 was $35.50M, a 70.67% increase from fiscal 2024.
- VIATRIS INC. payments for (proceeds from) other investing activities for fiscal 2024 was $20.80M, a 78.67% decline from fiscal 2023.
- VIATRIS INC. payments for (proceeds from) other investing activities for fiscal 2023 was $97.50M, a 163.51% increase from fiscal 2022.
- VIATRIS INC. payments for (proceeds from) other investing activities for fiscal 2022 was $37.00M, a 29.12% decline from fiscal 2021.
| Period end | Payments for (Proceeds from) Other Investing Activities 3 month | Payments for (Proceeds from) Other Investing Activities 6 month | Payments for (Proceeds from) Other Investing Activities 9 month | Payments for (Proceeds from) Other Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $83.00M 10-Q · filed 2026-08-06 | $85.60M derived: sum of 3 quarters · filed 2026-08-06 | $98.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $82.00M 10-Q · filed 2026-05-07 | $84.60M derived: sum of 2 quarters · filed 2026-05-07 | $97.50M derived: sum of 3 quarters · filed 2026-05-07 | $98.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.50M derived: sum of 2 quarters · filed 2026-02-26 | $16.70M derived: sum of 3 quarters · filed 2026-08-06 | $35.50M 10-K · filed 2026-02-26 |
| 2025-09-30 | $12.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.10M derived: sum of 2 quarters · filed 2026-08-06 | $32.90M 10-Q · filed 2025-11-06 | $33.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $20.00M 10-Q · filed 2026-08-06 | $20.70M derived: sum of 3 quarters · filed 2026-08-06 | $29.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $18.80M 10-Q · filed 2026-05-07 | $19.50M derived: sum of 2 quarters · filed 2026-05-07 | $27.90M derived: sum of 3 quarters · filed 2026-05-07 | $38.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.10M derived: sum of 2 quarters · filed 2026-02-26 | $19.80M derived: sum of 3 quarters · filed 2026-02-26 | $20.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.10M derived: sum of 2 quarters · filed 2025-11-06 | $20.10M 10-Q · filed 2025-11-06 | $55.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.70M 10-Q · filed 2025-08-07 | $47.10M derived: sum of 3 quarters · filed 2026-02-26 | $53.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.00M 10-Q · filed 2025-05-08 | $36.40M derived: sum of 2 quarters · filed 2026-02-26 | $42.60M derived: sum of 3 quarters · filed 2026-02-26 | $63.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $35.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $41.60M derived: sum of 2 quarters · filed 2026-02-26 | $62.80M derived: sum of 3 quarters · filed 2026-02-26 | $97.50M 10-K · filed 2026-02-26 |
| 2023-09-30 | $6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $27.40M derived: sum of 2 quarters · filed 2024-11-07 | $62.10M 10-Q · filed 2024-11-07 | $74.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $21.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $55.90M 10-Q · filed 2024-08-08 | $68.10M derived: sum of 3 quarters · filed 2025-02-27 | $79.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $34.70M 10-Q · filed 2024-05-09 | $46.90M derived: sum of 2 quarters · filed 2025-02-27 | $58.70M derived: sum of 3 quarters · filed 2025-02-27 | $64.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $12.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $24.00M derived: sum of 2 quarters · filed 2025-02-27 | $29.60M derived: sum of 3 quarters · filed 2025-02-27 | $37.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $11.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $17.40M derived: sum of 2 quarters · filed 2023-11-08 | $24.80M 10-Q · filed 2023-11-08 | $48.80M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $13.00M 10-Q · filed 2023-08-07 | $37.00M derived: sum of 3 quarters · filed 2024-02-28 | $47.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $7.40M 10-Q · filed 2023-05-08 | $31.40M derived: sum of 2 quarters · filed 2024-02-28 | $42.30M derived: sum of 3 quarters · filed 2024-02-28 | $55.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $34.90M derived: sum of 2 quarters · filed 2024-02-28 | $48.50M derived: sum of 3 quarters · filed 2024-02-28 | $52.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $10.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $24.50M derived: sum of 2 quarters · filed 2022-11-07 | $28.20M 10-Q · filed 2022-11-07 | $369.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $13.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $17.30M 10-Q · filed 2022-08-08 | $358.20M derived: sum of 3 quarters · filed 2023-02-27 | $379.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $3.70M 10-Q · filed 2022-05-09 | $344.60M derived: sum of 2 quarters · filed 2023-02-27 | $365.50M derived: sum of 3 quarters · filed 2023-02-27 | $374.80M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $340.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $361.80M derived: sum of 2 quarters · filed 2023-02-27 | $371.10M derived: sum of 3 quarters · filed 2023-02-27 | $438.20M 10-K · filed 2023-02-27 |
| 2020-09-30 | $20.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $30.20M derived: sum of 2 quarters · filed 2021-11-08 | $97.30M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $9.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $76.40M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $67.10M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $192.80M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $943.50M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |